- Home
- News
- Articles+
- Aerospace
- Artificial Intelligence
- Agriculture
- Alternate Dispute Resolution
- Arbitration & Mediation
- Banking and Finance
- Bankruptcy
- Book Review
- Bribery & Corruption
- Commercial Litigation
- Competition Law
- Conference Reports
- Consumer Products
- Contract
- Corporate Governance
- Corporate Law
- Covid-19
- Cryptocurrency
- Cybersecurity
- Data Protection
- Defence
- Digital Economy
- E-commerce
- Employment Law
- Energy and Natural Resources
- Entertainment and Sports Law
- Environmental Law
- Environmental, Social, and Governance
- Foreign Direct Investment
- Food and Beverage
- Gaming
- Health Care
- IBC Diaries
- In Focus
- Inclusion & Diversity
- Insurance Law
- Intellectual Property
- International Law
- IP & Tech Era
- Know the Law
- Labour Laws
- Law & Policy and Regulation
- Litigation
- Litigation Funding
- Manufacturing
- Mergers & Acquisitions
- NFTs
- Privacy
- Private Equity
- Project Finance
- Real Estate
- Risk and Compliance
- Student Corner
- Take On Board
- Tax
- Technology Media and Telecom
- Tributes
- Viewpoint
- Zoom In
- Law Firms
- In-House
- Rankings
- E-Magazine
- Legal Era TV
- Events
- Middle East
- Africa
- News
- Articles
- Aerospace
- Artificial Intelligence
- Agriculture
- Alternate Dispute Resolution
- Arbitration & Mediation
- Banking and Finance
- Bankruptcy
- Book Review
- Bribery & Corruption
- Commercial Litigation
- Competition Law
- Conference Reports
- Consumer Products
- Contract
- Corporate Governance
- Corporate Law
- Covid-19
- Cryptocurrency
- Cybersecurity
- Data Protection
- Defence
- Digital Economy
- E-commerce
- Employment Law
- Energy and Natural Resources
- Entertainment and Sports Law
- Environmental Law
- Environmental, Social, and Governance
- Foreign Direct Investment
- Food and Beverage
- Gaming
- Health Care
- IBC Diaries
- In Focus
- Inclusion & Diversity
- Insurance Law
- Intellectual Property
- International Law
- IP & Tech Era
- Know the Law
- Labour Laws
- Law & Policy and Regulation
- Litigation
- Litigation Funding
- Manufacturing
- Mergers & Acquisitions
- NFTs
- Privacy
- Private Equity
- Project Finance
- Real Estate
- Risk and Compliance
- Student Corner
- Take On Board
- Tax
- Technology Media and Telecom
- Tributes
- Viewpoint
- Zoom In
- Law Firms
- In-House
- Rankings
- E-Magazine
- Legal Era TV
- Events
- Middle East
- Africa
Matthew Fedowitz is a seasoned life sciences attorney specializing in intellectual property litigation, patent portfolio development, and FDA regulatory counseling. With deep expertise in the pharmaceutical, life sciences, and medical device sectors, Matthew helps clients align legal strategies with their business objectives, navigating complex patent prosecution, inter partes proceedings before the Patent Trial and Appeal Board, and federal district court litigation.
Before entering private practice, Matthew worked at the U.S. Patent and Trademark Office, focusing on pharmaceutical-related patent applications, and at the FDA’s Office of Generic Drugs. His unique background enables him to guide clients through patent validity, freedom-to-operate analyses, and strategic dispute resolution.
Matthew has been recognized consistently by IAM Patent 1000, Washington D.C. Super Lawyers, Virginia and D.C. Rising Stars, and The Best Lawyers in America for Patent Law. He represents major pharmaceutical companies in high-stakes patent litigation and intellectual property matters, including multiple notable cases in Delaware, New Jersey, and other federal courts.
Outside the office, Matthew is an avid road cyclist and outdoor enthusiast. He is actively involved with professional organizations such as the American Bar Association and the Intellectual Property Owners Association, serving as Chair and Secretary of the Intellectual Property Section of the Bar Association of the District of Columbia.



